Background and Objectives: Tumor markers are burgeoning concept in the healthcare industry. It has not been fool proof in that their levels may fluctuate with time, may not rise consistently in all cancers, may be present in considerable amount in non-cancer patients, standardization has not been done. But their ease of assay with ELISA and chemiluminescence immunoassay techniques with just a blood sample collected in the clot activator vacationer, allowed to clot and the tube centrifuged to separate the serum and cells, and the serum is analysed using Beckman coulter Access 2 auto analyzer. It is convenient, time saving, cost effective, and large number of patient samples can be processed in a short time. It gives valuable information about the screening, diagnoses, prognosis, monitoring, surveillance, and progression of cancer in all stages, about planning treatment and monitoring recurrence. Lately a surrogate marker for tissue biopsy, called the liquid biopsy has come in vogue where the plasma is analysed for circulating tumor cells or circulating tumor DNA. The implications of tumor marker research will gain momentum with advancement of molecular diagnoses.
KeywordsTumor Index Substances; Immunoassay; Liquid Biopsy; Single Nucleotide Polymorphism
Published Date: 2023-02-23; Received Date: 2023-01-28
